Halozyme Beats Q2 Earnings Estimates, Raises 2026 Revenue Outlook
Halozyme Therapeutics reported second-quarter earnings of $2.28 per share, surpassing estimates by nearly 25%. This marks a significant increase of 48.1% year-over-year. Total revenues rose to $481 million, up 48% from the same period last year and exceeding expectations.
The growth in revenue is attributed primarily to increased product sales and higher royalty payments. The company has partnerships with major pharmaceutical companies such as Johnson & Johnson for its subcutaneous Darzalex (daratumumab) and argenx for Vyvgart Hytrulo, both of which utilize Halozyme's Enhanze technology.
Shares of Halozyme have rallied 27.5% year-to-date, outperforming the industry average of 4.4%. The company has also raised its total revenue guidance for 2026 to a range of $1.84 billion to $1.91 billion.